gms | German Medical Science

35. Internationaler Kongress der Deutschen Ophthalmochirurgie (DOC)

15.06. - 17.06.2023, Nürnberg

Article

Send article

Immune checkpoint inhibitors and ophthalmic related side effects. Pembrolizumab, Nivolumab and Ipilimumab side effects review: a literature review article

Meeting Abstract

Search Medline for

  • Khalid Alburayk - Cornea, Ophthalmology, AlKhobar, Saudi-Arabien

35. Internationaler Kongress der Deutschen Ophthalmochirurgie (DOC). Nürnberg, 15.-17.06.2023. Düsseldorf: German Medical Science GMS Publishing House; 2023. DocEPO 3.2

doi: 10.3205/23doc079, urn:nbn:de:0183-23doc0796

Published: June 13, 2023

© 2023 Alburayk.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Background: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that deactivate inhibitory receptors of immune system and restore the antitumor immunity. Their excessive use in treating carcinomas is beneficial on one side but their post-treatment adverse effects, are also a hallmark. 5 Immune-related adverse events (IRAEs), which can affect any organ system and occur in 70–90% of patients.

Aims and Objectives: To asses all of the reported ophthalmic complications of Pembrolizumab, Ipilimumab and Nivolumab treatment and their prevalence in order to early diagnose and manage ophthalmic IRAEs as per departmental protocol.

Method: Systemic review was conducted according to the Cochrane handbook of systemic reviews and ophthalmology book of systemic reviews and reported based on PRISMA.

Results: Our systematic review included 25 articles, based on inclusion criteria. Which showed different types of ophthalmic related side effects.

Conclusion: Usage of ICIs carry a risk of developing ophthalmic side effects in which some of them are site threatening, proper identification and appropriate management may prevent permanent ocular damage.